Navigation Links
Vasogen Provides Update on ACCLAIM II Program
Date:3/3/2008

AIM II study protocol and statistical analysis plan and to work with members of the ACCLAIM II Steering Committee and our statistical advisors to address the FDA's concerns. We will provide an update to shareholders once we have had further discussions with the FDA."

Vasogen retained Berry Consultants and Dr. Donald A. Berry, Head, Division of Quantitative Sciences and Chairman, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, and a world recognized authority in the area of Bayesian and adaptive trial design. Dr. Berry has been assisting Vasogen throughout the development of ACCLAIM II study design. Vasogen has also established the ACCLAIM II Steering Committee led by James B. Young, MD, Chairman, Division of Medicine at the Cleveland Clinic Foundation and Medical Director, Kaufman Center for Heart Failure, appointed Chairs for the Data and Safety Monitoring Board (DSMB) and Central Endpoint Committee (CEC), and has drafted the key trial documents necessary to initiate the trial. The Company has also selected a CRO and has identified and received commitments from U.S.-based clinical sites to participate in the study. The majority of these sites participated in the first ACCLAIM trial and were selected on the basis of their ability to quickly recruit patients and conduct high quality research.

About Vasogen:

Vasogen is a biotechnology company engaged in the research and commercial development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. The Company's lead product, the Celacade(TM) System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is being marketed in the EU by Grupo Ferrer Internacional, S.A. Celacade is also in late-s
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. CardioDynamics Provides 2007 Shareholder Meeting Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... July 14, 2014 Throughout this ... across the clinical trials space, representing 38 countries ... series entitled “Optimizing Patient Participation in Clinical Trials. ... off with internationally renowned R&D expert, Ken Getz, ... on Reinventing Drug Development through Patient Centricity. , ...
(Date:7/14/2014)... Mass. , July 14, 2014 Minerva ... the development of new therapies to treat neuropsychiatric diseases ... has been appointed vice president of finance and ... Mr. Ahlholm is a senior executive with more than ... at technology and life science companies. His background includes ...
(Date:7/14/2014)... Mateo, CA (PRWEB) July 14, 2014 ... CONNECT patient registry platform, announced that three ... muscular dystrophies; the Phelan-McDermid Syndrome International Registry; ... Nephrotic Syndrome—have been awarded contracts by the ... of the creation of a new health ...
(Date:7/13/2014)... R.I. (Brown University) -- The discovery 30 years ago ... an explosion of nanotechnology research. Now, there appears to ... from Brown University, Shanxi University and Tsinghua University in ... atoms forms a hollow molecular cage similar to a ... boron cage structurepreviously only a matter of speculationdoes indeed ...
Breaking Biology Technology:Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 3Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 4Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 5Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer 2PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 3
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) today announced ... scheduled to present at the Rodman & Renshaw,10th Annual ... Tuesday, November 11th, 2008 at 2:50 p.m. Eastern Time ... 2008 at the,Palace Hotel in New York., The ...
... Driven by the emergence of innovative technologies ... and proteomics, world market for drug discovery ... by 2012. Despite the heavy costs involved ... pharmaceutical research and development are reaching new ...
... of Wisconsin-Madison engineers and physicists have developed a method ... that could lay the foundation for faster flexible electronics. ... electronic devices. Silicon thin films could be the basis ... inducing strain into the silicon increases device speed, yet ...
Cached Biology Technology:Global Drug Discovery Technologies Market to Exceed $57 Billion by 2012, According to a New Report by Global Industry Analysts 2Global Drug Discovery Technologies Market to Exceed $57 Billion by 2012, According to a New Report by Global Industry Analysts 3Global Drug Discovery Technologies Market to Exceed $57 Billion by 2012, According to a New Report by Global Industry Analysts 4Stretching silicon: A new method to measure how strain affects semiconductors 2
(Date:7/14/2014)... of Kansas scientists to the discovery and description of ... collections specimen, which turned out to represent a new genus ... ripidiine wedge beetle from Borneo is discussed in a recent ... . , The holotype male, and only known specimen ... in Borneo but subsequent to this it was transferred among ...
(Date:7/14/2014)... environment manage much better in the struggle for survival ... A world without bees would be a whole lot ... million to 1 billion Danish kroner are earned annually ... and pollinating a wide range of crops from apples ... the world are under pressure from pesticides, mites, viruses, ...
(Date:7/14/2014)... The Roquin protein, discovered in 2005, controls T-cell ... certain mRNAs. In doing so, it helps to ... the body,s own structures that can lead to ... Autoimmune diseases affect between five and ten per ... a result of complex environmental influences when a ...
Breaking Biology News(10 mins):Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 2Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 3Best for bees to be stay-at-homes 2Molecular mechanisms underlying the prevention of autoim-munity by Roquin revealed 2
... Since the 1960s, psychiatrists have been hunting for substances ... high levels to produce the symptoms associated with schizophrenia. ... might be related to the hallucinogens phencyclidine (PCP) or ... of psychotic symptoms in schizophrenia. This "auto-intoxication" hypothesis led ...
... March 14, 2013 In the largest ever ... genetics company, identified 20 new genetic associations for myopia, ... in the study, which was specific to individuals of ... data and survey responses from more than 50,000 23andMe ...
... to feed, some whales throw their jaws wide and engulf ... along with their mouths agape (ram or skim feeding), yet ... whales, mouths to filter nutrition from the ocean: baleen. Alexander ... how the hairy substance actually traps morsels of food. ,The ...
Cached Biology News:The mysterious GRIN3A and the cause of schizophrenia 223andMe identifies multiple genetic factors impacting development of nearsightedness 2Whale's streaming baleen tangles to trap food 2
... Serum; U.S. sourced, ideal for ... quality; Low hemoglobin; Endotoxin: < ... of US origin; U.S. sourced, ... an uncompromising quality. Low hemoglobin ...
Chicken polyclonal to ytzF ( Abpromise for all tested applications). Antigen: Full length protein...
Fetal Calf Serum Replacement (Bistec) serum...
...
Biology Products: